VEGFA and neoplasm: As an alternative strategy to overcome anti-VEGF resistance, tumor-derived EC-specific targeting by the pharmacological inhibition or genetic deletion of the PDGF signaling pathway significantly sensitizes tumors to anti-VEGF therapy.